NASDAQ:RLMD
Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. reported net income of −$57.4M in fiscal 2025. The diluted share count rose 30.9%.Summary generated from Relmada Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 19, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−94.0%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+30.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −126 | −161 | −104 | −84 | −59 |
| Net income | −126 | −157 | −99 | −80 | −57 |
| Free cash flow | n/a | n/a | n/a | n/a | n/a |
Recent filings
- 4Insider transaction report
Sep 11, 2026 - 4Insider transaction report
Sep 11, 2026 - 8-KOther events
Sep 8, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KRegulation FD disclosure
Jul 28, 2026 - 8-KAmendment to articles or bylaws
May 28, 2026 - 8-KResults of operations and financial condition
May 12, 2026